A biotechnology company is developing a way to use a biomarker associated with healthy embryos to improve outcomes for women receiving in vitro fertilization treatment. Bioincept has raised half of a $6.5 million fundraising target, according to an amended Form D filed with the U.S. Securities and Exchange Commission. The goal is to support human trials which are expected to begin this summer, according to a source familiar with the company.
Hey, check out all the engineering jobs. Post your resume today!
